Skip to main content
You have permission to edit this article.
Edit

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2023 Financial, Corporate Report

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, is reporting its financial results for Q1 2023, or the period ended June 30, 2022. In addition, the company also released a corporate update for the company, noting that evaluation of its proprietary PALISADE-1 continues with interim analysis of PALISADE-2 beginning. The company also stated that preliminary data from some 200 subjects in the PALISADE open-label safety study suggests that continued use of POAI’s PH94B as needed has potential to achieve cumulative functional improvement in the severity of social anxiety disorder (“SAD”). “We remain steadfast in our commitment to change the trajectory of mental health care for millions of people affected by anxiety and depression disorders,” said VistaGen CEO Shawn Singh in the press release. “While we examine the results of our PALISADE-1 Phase 3 study in social anxiety disorder, we have paused enrollment in our PALISADE-2 Phase 3 study and have engaged an independent biostatistician to conduct an interim analysis of data collected to date. We then plan to meet with the FDA to pursue a consensus path forward for further phase 3 development of PH94B in social anxiety disorder. . . . We continue to believe in PH94B’s potential to help individuals suffering from social anxiety disorder. We are further encouraged by preliminary data from a cohort of nearly 200 patients in our PALISADE open-label safety study who have completed three months of acute, as-needed use of PH94B. These preliminary data suggest that repeated acute, as-needed use of PH94B over an extended period of time has potential to increasingly relieve symptoms of social anxiety disorder, as measured by the Liebowitz Social Anxiety Scale, or LSAS, which historically has been the diagnostic gold standard for clinical assessment of social anxiety disorder. . . . Our mission is to transform lives, and we have a strong pipeline and team in place to accomplish that goal.”

To view the full press release, visit https://ibn.fm/xU7st

About VistaGen Therapeutics Inc.

VistaGen is a late clinical-stage, CNS-focused, biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing therapeutics with the potential to be faster acting and with fewer side effects and safety concerns than those that are currently available. VistaGen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherines, which are odorless and tasteless investigational neuroactive steroids designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic uptake or direct activity on CNS neurons in the brain. VistaGen is passionate about transforming mental-health care and redefining what is possible in the treatment of anxiety and depression. For more information about the company, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.